Department of Clinical Sciences Lund, Skane University Hospital, Lund University, Lund, Sweden.
Department of Urology, Coimbra University Hospital, Coimbra, Portugal.
World J Urol. 2018 Dec;36(12):1953-1959. doi: 10.1007/s00345-018-2338-z. Epub 2018 May 16.
Patients with localised renal cell carcinoma (RCC) receiving curative surgery, either radical or partial nephrectomy, have been shown in contemporary studies to develop recurrence within 5 years in 20-30% of case. Therefore, post-operative follow-up (FU) imaging plays a crucial role in detecting recurrent or metastatic disease. A number of prognostic scores have been developed to predict risk of recurrence. This review summarises the current knowledge on established FU protocols and their limitations.
A non-systematic literature search was conducted using Medline. Furthermore, major guidelines [European Association of Urology (EAU), American Urological Association (AUA) and National Comprehensive Cancer Network (NCCN)] were reviewed and assessed.
The EAU, AUA and NCCN post-operative follow-up guidelines differ in the frequency and type of imaging modalities recommended. The optimal duration of follow-up remains to be elucidated as does the impact of follow-up protocols on patient outcomes and quality of life. Established follow-up protocols do not take non-RCC-related factors, such as patient age and performance status into account. However, in the future individualised duration of FU based on competing risks of cancer recurrence and non-RCC death may be optimised, maximising resources and patient quality of life.
There is a clear need to establish evidence-based follow-up protocols and to assess the impact of follow-up protocols on individual patients and society.
在当代研究中,接受根治性或部分肾切除术治疗局限性肾细胞癌 (RCC) 的患者,在 5 年内有 20-30%的病例会复发。因此,术后随访 (FU) 影像学在检测复发性或转移性疾病方面起着至关重要的作用。已经开发了许多预后评分来预测复发风险。这篇综述总结了目前关于既定 FU 方案及其局限性的知识。
使用 Medline 进行了非系统性文献检索。此外,还回顾和评估了主要指南 [欧洲泌尿外科学会 (EAU)、美国泌尿外科学会 (AUA) 和国家综合癌症网络 (NCCN)]。
EAU、AUA 和 NCCN 的术后随访指南在推荐的影像学方式的频率和类型上存在差异。最佳随访持续时间仍有待阐明,随访方案对患者结局和生活质量的影响也有待阐明。既定的随访方案并未考虑非 RCC 相关因素,如患者年龄和身体状况。然而,在未来,基于癌症复发和非 RCC 死亡的竞争风险,可能会优化个体化 FU 持续时间,最大限度地利用资源并提高患者生活质量。
显然需要建立基于证据的随访方案,并评估随访方案对个体患者和社会的影响。